

<b>1</b>	<b>Type of Issue</b>	Initial Public offer
<b>2</b>	<b>Offer Size (Rs. Mn)</b>	<b>6,553.71</b>
	Fresh Issue Size (Rs. Mn)	-
	Offer for Sale (Rs Mn)	6,553.71
	<i>*Source: Prospectus for the offer dated December 10, 2025</i>	

<b>3</b>	<b>Grade of issue along with name of the rating agency</b>	
	<b>Name</b>	NA
	<b>Grade</b>	NA

<b>4</b>	<b>Subscription Level (Number of times)</b>	101.97
	<i>* excluding Eligible employee and Eligible shareholder reservation and after removing multiple and duplicate bids and technical</i>	
	<i>Source: Post Offer Report dated December 17, 2025</i>	

<b>5</b>	<b>QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges</b>	
	<b>Particulars</b>	<b>%</b>
	(i) On Allotment in the offer <sup>(1)</sup>	5.00
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (period ended December 31, 2025)	6.76
	(iii) at the end of 1st FY (March 31, 2026)	9.32
	(iv) at the end of 2nd FY (March 31, 2027)*	Not Available
	(v) at the end of 3rd FY (March 31, 2028)*	Not Available
	<i>*QIB Holding not disclosed as reporting for the relevant period/fiscal year has not been completed.</i>	
	<i>(1) Source: Post offer report and BSE website</i>	

<b>6</b>	<b>Financials of the issuer</b>			
				<i>(Rs. in Mn)</i>
	<b>Parameters</b>	<b>1st FY (March 31, 2026)</b>	<b>2nd FY (March 31, 2027)*</b>	<b>3rd FY (March 31, 2028)*</b>
	Income from operations	14,031.80	Not Available	Not Available
	Net Profit for the period	1,848.50	Not Available	Not Available
	Paid-up equity share capital	611.60	Not Available	Not Available
	Reserves excluding revaluation reserves	6,848.10	Not Available	Not Available
	<i>*Financials not available as reporting for the relevant years has not been completed.</i>			

<b>7</b>	<b>Trading Status</b>	
	The equity shares of CORONA Remedies Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")	
	The equity shares have not been suspended or delisted.	
	<b>Particulars</b>	<b>Status</b>
	(i) at the end of 1st FY (March 31, 2026)	Frequently Traded
	(ii) at the end of 2nd FY (March 31, 2027)*	Not Available
	(iii) at the end of 3rd FY (March 31, 2028)*	Not Available
	<i>* Trading status not disclosed as the relevant fiscal years have not been completed.</i>	

<b>8</b>	<b>Change in Directors of Issuer from the disclosures in the offer document<sup>#</sup></b>		
	<b>Particulars</b>	<b>Name of Director</b>	<b>Appointed/Resigned</b>
	(i) at the end of 1st FY (March 31, 2026)	No Change	No Change
	(ii) at the end of 2nd FY (March 31, 2027)*	NA	NA
	(iii) at the end of 3rd FY (March 31, 2028)*	NA	NA
	<i>* Relevant fiscal years have not been completed.</i>		
	<i># Source - Stock Exchange website</i>		

<b>9</b>	<b>Status of implementation of project/ commencement of commercial production</b>	
	(i) as disclosed in the offer document	Not applicable*
	(ii) Actual implementation	Not applicable*
	(iii) Reasons for delay in implementation, if any	Not applicable*
	<i>* Company did not undertake any implementation of project hence the same is not applicable</i>	

<b>10</b>	<b>Status of utilization of issue proceeds</b>
	The objects of the Offer were to (i) to carry out the Offer for Sale of 6,174,051 Equity Shares of face value of ₹ 10 each by the Selling Shareholders aggregating to ₹ 6,553.71 million; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges.

<b>11</b>	<b>Comments of monitoring agency, if applicable</b>	
	(i) Comments on use of funds	NA
	(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects	
	(iii) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Designated Stock Exchange  
Offer Price (Rs.)  
Listing Date

NSE  
1062.00  
15-Dec-25

Price parameters	At close of listing day (December 15, 2025)	Close of 30th calendar day from listing day <sup>(2)</sup> (January 13, 2026)	Close of 90th calendar day from listing day <sup>(3)</sup> (March 14, 2026)	As at the end of the 1st FY after the listing of the issue (31st March, 2026) <sup>(1)(4)</sup>		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE <sup>(5)</sup>	1,438.40	1,432.90	1,538.60	1,556.00	1,699.00	1,336.60
Nifty <sup>(5)</sup>	26,268.70	25,732.30	23,151.10	22,331.40	26,373.20	21,743.65
Sectoral Index <sup>(6)</sup>	Not comparable to any of the available sectoral indices			Not comparable to any of the available sectoral indices		
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2027) <sup>(1)(4)</sup>			As at the end of the 3rd FY after the listing of the issue (31st March, 2028) <sup>(1)(4)</sup>		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE <sup>(5)</sup>	NA	NA	NA	NA	NA	NA
Nifty <sup>(5)</sup>	NA	NA	NA	NA	NA	NA
Sectoral Index <sup>(6)</sup>	Not comparable to any of the available sectoral indices			Not comparable to any of the available sectoral indices		

\*Source: NSE website

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

(2) 30th calendar day is taken as listing date plus 29 calendar days

(3) 90th calendar day is taken as listing date plus 89 calendar days

(4) High and Low based on intra day prices

(5) In case of reporting dates falling on a trading holiday, values for the trading day immediately preceding the trading holiday have been considered.

(6) Comparable Sectoral index is not available

13 Basis for Offer Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2026)	At the end of 2nd FY (March 31, 2027) <sup>(3)</sup>	At the end of 3rd FY (March 31, 2028) <sup>(3)</sup>
EPS (₹)	<b>Issuer:</b>			
	Consolidated (Basic)	24.43	30.27	Not Available
	Consolidated (Diluted)	24.43	30.27	Not Available
	<b>Peer Group: (Diluted)</b>			
	Abbott India Limited	665.62	730.36	Not Available
	Alkem Laboratories Limited	181.11	192.51	Not Available
	Eris Lifesciences Limited	25.81	45.26	Not Available
	GlaxoSmithKline Pharmaceuticals Limited	54.76	61.15	Not Available
	J.B. Chemicals & Pharmaceuticals Limited	41.56	44.45	Not Available
	Mankind Pharma Limited	49.20	46.28	Not Available
	Pfizer Limited	167.79	157.92	Not Available
	Sanofi India Limited	179.46	Not Available	Not Available
	Torrent Pharmaceuticals Limited	56.47	63.92	Not Available
	<b>Industry Avg:</b>	<b>157.98</b>	<b>167.73</b>	Not Available
Price to Earnings Ratio (P/E)	<b>Issuer:</b>			
	Consolidated (Consolidated)	NA	51.41	Not Available
	<b>Peer Group (Consolidated)#</b>			
	Abbott India Limited	45.17	35.49	Not Available
	Alkem Laboratories Limited	31.39	27.55	Not Available
	Eris Lifesciences Limited	61.81	28.68	Not Available
	GlaxoSmithKline Pharmaceuticals Limited	46.87	37.34	Not Available
	J.B. Chemicals & Pharmaceuticals Limited	42.60	46.42	Not Available
	Mankind Pharma Limited	45.77	43.34	Not Available
	Pfizer Limited	29.63	29.89	Not Available
	Sanofi India Limited	24.47	Not Available	Not Available
	Torrent Pharmaceuticals Limited	65.91	66.03	Not Available
	<b>Industry Avg:</b>	<b>43.74</b>	<b>39.34</b>	Not Available
	Return on Net Worth (%)	<b>Issuer:</b>		
Consolidated		24.65	27.00	Not Available
<b>Peer Group: (Consolidated)#</b>				
Abbott India Limited		33.41	32.65	Not Available
Alkem Laboratories Limited		18.07	17.04	Not Available
Eris Lifesciences Limited		12.21	16.65	Not Available
GlaxoSmithKline Pharmaceuticals Limited		47.54	49.38	Not Available
J.B. Chemicals & Pharmaceuticals Limited		19.21	17.12	Not Available
Mankind Pharma Limited		13.89	11.92	Not Available
Pfizer Limited		18.20	17.38	Not Available
Sanofi India Limited		48.05	Not Available	Not Available
Torrent Pharmaceuticals Limited		25.18	26.01	Not Available
<b>Industry Avg:</b>		<b>26.20</b>	<b>23.52</b>	Not Available
NAV per Equity Share (₹ per share)		<b>Issuer:</b>		
	Consolidated	99.14	122.12	Not Available
	<b>Peer Group: (Consolidated)#</b>			
	Abbott India Limited	1992.14	2,364.95	Not Available
	Alkem Laboratories Limited	1002.37	1,200.09	Not Available
Eris Lifesciences Limited	209.73	281.19	Not Available	

GlaxoSmithKline Pharmaceuticals Limited	115.19	243.10	Not Available	Not Available
J.B. Chemicals & Pharmaceuticals Limited	220.88	259.05	Not Available	Not Available
Mankind Pharma Limited	352.51	401.16	Not Available	Not Available
Pfizer Limited	921.88	918.71	Not Available	Not Available
Sanofi India Limited	373.68	Not Available	Not Available	Not Available
Torrent Pharmaceuticals Limited	224.28	1,062.77	Not Available	Not Available
<b>Industry Avg:</b>	<b>601.41</b>	<b>841.38</b>	Not Available	Not Available
<b>Revenue from operations (in ₹million)</b>				
<b>Issuer:</b>				
Consolidated	11964.15	Not Available	Not Available	Not Available
<b>Peer Group: (Consolidated)#</b>				
Abbott India Limited	64091.50	69,290.50	Not Available	Not Available
Alkem Laboratories Limited	129645.20	1,47,122.70	Not Available	Not Available
Eris Lifesciences Limited	28936.40	31,294.20	Not Available	Not Available
GlaxoSmithKline Pharmaceuticals Limited	37492.10	38,216.70	Not Available	Not Available
J.B. Chemicals & Pharmaceuticals Limited	39179.89	41,477.90	Not Available	Not Available
Mankind Pharma Limited	122074.40	1,42,776.40	Not Available	Not Available
Pfizer Limited	22813.50	25,196.50	Not Available	Not Available
Sanofi India Limited	20132.00	Not Available	Not Available	Not Available
Torrent Pharmaceuticals Limited	115160.90	1,39,800.00	Not Available	Not Available
<b>Industry Avg:</b>	<b>64,392</b>	<b>79,396.86</b>	Not Available	Not Available

(1)\*Source: Prospectus for the offer dated December 10, 2025; #For Abott India Limited, standalone figures were considered and included in the offer documents.

(2) Information sourced from financials filed by the Issuer Company and Peers on the stock exchanges

(3) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

1.P/E Ratio has been computed based on the closing market price of equity shares on November 28, 2025, divided by the Diluted EPS.

2. Return on net worth is the restated profit attributable to owners of the Company divided by the net worth at the end of the period/ year.

3. Net asset value per equity share as at a period/year represents net worth as of the end of the period/year divided by the weighted average outstanding equity shares considered for EPS as the end of the period/year.

4. J. B. Chemicals & Pharmaceuticals Limited has announced a stock split from ₹2.00 per equity share to ₹1.00 per equity share with ex-split date on September 18, 2023. Accordingly, Net asset value per equity share has been adjusted to reflect the stock split.

#### Any other material information

14

Date	Announcement
15 December 2025	Listing of Equity Shares of CORONA Remedies Limited
15 December 2025	Closure of Trading Window
15 December 2025	Intimation of continuation of Ms. Chetna Dharajiya as the Compliance Officer of CORONA Remedies Limited pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements), 2015
15 December 2025	Intimation of continuation of Bigshare Services Private Limited as the Registrar and Share Transfer Agent of CORONA Remedies Limited
15 December 2025	Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
15 December 2025	Intimation Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation, 2015 - Names of the Key Managerial Personnels of the Company who are authorised to determine the materiality of an event or information and for the purpose of making disclosure to the stock exchanges under Regulation30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 – Commencement of Commercial Production of tablet(s) / capsule(s) at the Bhayla manufacturing facility (Facility) of the Company.
22 December 2025	Intimation For Appointment Of Investor Relations Agency - Strategic Growth Advisors Pvt. Ltd
23 December 2025	Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For The Second Quarter And Half Year Ended On September 30, 2025
26 December 2025	Intimation for updation of CIN of the
01 January 2026	Board at its meeting inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the second quarter and half year ended on September 30, 2025.
02 January 2026	Intitimation of Financial Results for the second quarter and half year ended September 30, 2025
02 January 2026	Press Release on financial results for
02 January 2026	Newspaper Publication of Unaudited Financial Results for the second quarter and half year ended September 30, 2025
03 January 2026	Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the third quarter ended December 31, 2025
06 January 2026	Intimation under Regulation 30-GMP
19 January 2026	Corona Remedies Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2026 ,inter alia, to consider and approve Board Meeting intimation for consideration and approval of Unaudited
27 January 2026	Intimation of violation under the Company's Code of Conduct for Regulating, Monitoring and Reporting of Insider Trading in securities and the SEBI (Prohibition of Insider Trading) Regulations, 2015
30 January 2026	Board approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the third quarter and nine months ended December 31, 2025.
02 February 2026	Press Release on financial results for Q3FY26
02 February 2026	Credit Rating – Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
03 February 2026	Newspaper Publication of Unaudited Financial Results for the third quarter and nine months ended December 31, 2025
03 February 2026	Audio Recording of conference call with Analyst / Investor on financial results for Q3 and Three Months and Nine Months ended December 31, 2025
10 February 2026	Transcript of Earnings Conference Call with Analyst / Investor on Financial Results for the third quarter and nine months ended December 31, 2025
17 February 2026	Intimation of participation in Analyst / Investor Conference
27 February 2026	Intimation of Schedule of Analyst / Investor Meeting
07 March 2026	Intimation of Schedule of Analyst / Investor Meeting
30 March 2026	Intimation of Closure of Trading Window
30 March 2026	Press Release titled "CORONA Remedies announces strategic acquisition of Wokadine in India"
07 April 2026	Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the fourth quarter ended March 31, 2026
30 April 2026	Board Meeting Intimation for Consideration And Approval Of Audited Financial Results On Standalone And Consolidated Basis For The Fourth Quarter And Year Ended On March 31, 2026
30 April 2026	Intimation of Schedule of Analyst / Investor Call
11 May 2026	Outcome Of Board Meeting
11 May 2026	Financial Results for the Fourth Quarter and Year ended March 31, 2026
11 May 2026	Press Release on financial results for Q4FY26 and Year ended March 31, 2026
11 May 2026	Appointment of M/s. Walker Chandiook & Co LLP, Chartered Accountants as Statutory Auditor of the Company for five consecutive years commencing from conclusion of the 22nd AGM to be held for the F.Y. 2025-26 till the conclusion of the 27th AGM to be held for the F.Y. 2030-31
11 May 2026	Re-appointment of M/s. Dhara Patel, peer reviewed Company Secretary Firm as the Secretarial Auditor of the Company for five financial years commencing from F.Y. 2026-27
11 May 2026	Appointment of M/s. Shah & Shah Associates, Chartered Accountants as Internal Auditor of the Company for the F.Y. 2026-27
11 May 2026	Re-appointment of M/s. Manish B. Analkat as the Cost Auditor of the Company for F.Y. 2026-27
11 May 2026	Re-appointment of Dr. Kirtikumhar Mehta (DIN: 00385658) as the Non Executive Director and Chairman of the Company for the term of five consecutive Financial Years with effective from April 01, 2027
11 May 2026	The Board at its meeting held today has recommended Final Dividend (for the F.Y. 2025-26) of Rs. 10/- (100%) per equity share of face value of Rs. 10/- each to the shareholders for their approval at the ensuing AGM of the Company
11 May 2026	Record date for the purpose of Final Dividend for the F.Y. 2025-26 is June 19, 2026
11 May 2026	Analyst/Investor Presentation
12 May 2026	Newspaper Publication of Audited Financial Results for the fourth quarter and year ended on March 31, 2026
12 May 2026	Audio Recording of conference call with Analyst / Investor on Financial Results for the fourth quarter and year ended March 31, 2026
12 May 2026	Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026
12 May 2026	Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026
18 May 2026	Transcript of Earnings call with Analyst/Investor on Financial Results for the fourth quarter and year ended March 31, 2026

19 May 2026  
21 May 2026  
28 May 2026

Intimation of participation in Analyst / Investor Conference  
Communication to Shareholders - Intimation on Tax Deduction on Dividend  
Press Release - Receipt of EU-GMP Certification

*Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com)*

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.